XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 31.38

-2.5%

11:25 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bluegreen who wrote (16502)	12/3/2003 2:42:13 PM
From: Cacaito	Read Replies (1) of 17367

Wrong in 2004, and Wrong in his comparison of Raptiva vs Amevive. Raptiva IS an IMMUNESUPPRESANT drug, they are not just an "immunemodulator" and their side effects profile is not better than Amevive, neither is the efficacy. That Fortis guy is obviously pandering to his own investment, fine, I am pandering my own too !!! But, xoma will not be profitable in 2004, xoma will be lucky if they can ramp up $50 millions in 2004. Then it will give xoma $12.5 millions, that xoma can burn in one quarter. Raptiva sales should go near $250 millions for xoma to be profitable, assuming current burning cash and current number of shares. xoma is not awash in cash, xoma is washing cash for Dna.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next